R&D Trends

Janssen R&D, Viiv Healthcare collaborate on maintenance treatment for HIV

Friday, June 13, 2014 01:08 PM

Janssen R&D Ireland has entered into a collaboration with ViiV Healthcare to develop and commercialize a new, single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT) and ViiV's Integrase Inhibitor dolutegravir (marketed as TIVICAY) as the sole active ingredients for the maintenance treatment of people living with human immunodeficiency virus (HIV). The companies will further investigate development of this drug combination for pediatric use.

More... »

WIRB Copernicus Group

AstraZeneca in-licenses Synairgen's SNG001 for asthma in $232M deal

Thursday, June 12, 2014 01:38 PM

AstraZeneca has inked a global license agreement with Synairgen, a U.K. company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.

More... »


X-Chem, Pfizer enter multi-target collaboration

Thursday, June 12, 2014 01:35 PM

X-Chem, a privately held biotechnology company applying its discovery capabilities to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Pfizer. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.

More... »

Seattle Children's Research Institute, Kineta partner for autoimmune research

Thursday, June 12, 2014 12:33 AM

Seattle Children's Research Institute and Kineta, a Seattle, Wash.-based privately held biotechnology company, have launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases such as multiple sclerosis, type 1 diabetes and rheumatoid arthritis.

More... »

NIH embraces 12-year scientific vision for BRAIN Initiative

Wednesday, June 11, 2014 12:50 PM

A federal report calls for $4.5 billion in funding for brain research over the next 12 years. The long-term scientific vision of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative was presented to NIH Director Francis S. Collins, M.D., Ph.D., by his Advisory Committee to the Director (ACD). Collins accepted the recommendations, calling the report bold and game changing.

More... »

Medical Research Council, Technology Strategy Board announce $80.6M for biomedical research

Wednesday, June 11, 2014 12:47 PM

Science MinisterDavid Willetts has announced $80.6million of new investment in biomedical research. The Biomedical Catalyst is a scheme run jointly by the Medical Research Council and the U.K.’s innovation agency, the Technology Strategy Board, to find solutions to healthcare challenges. It supports the best life science opportunities in the U.K. to help speed up the transition from discovery science to commercial application.

More... »

Pulmonary Fibrosis Foundation, Biogen Idec partner on PFF Patient Registry

Wednesday, June 11, 2014 12:44 PM

The Pulmonary Fibrosis Foundation (PFF) has partnered with Biogen Idec to support the PFF Patient Registry.

More... »

Synthetic Biologics, Enterome Bioscience collaborate

Wednesday, June 11, 2014 12:43 PM

Synthetic Biologics, a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience, a developer of innovative disease management solutions based on a deep understanding of the gut microbiome, have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

More... »

PaxVax, UC San Diego collaborate to develop herpes vaccine

Wednesday, June 11, 2014 12:40 PM

PaxVax, a specialty vaccine company with a commercial focus on travel and biodefense, has entered an R&D collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.

More... »

Halfpenny Technologies, Janssen Diagnostics ink agreement

Wednesday, June 11, 2014 12:40 PM

Halfpenny Technologies, a provider of a cloud-based, secure, scalable, vendor-neutral clinical data exchange platform, has entered into an agreement with Janssen Diagnostics to supplement the clinical data needs of Janssen’s AVIGA EHR. The AVIGA electronic health record is designed to support the data and federal reporting needs of providers specializing in HIV/AIDS healthcare.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs